Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women

NCT02444390 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT02444390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02444390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women
Lead sponsor
UNICANCER
Phase
Not applicable
Overall status
Completed
Start date
May 19, 2015
Completion date
July 1, 2022
Enrollment
150 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer